Clinical Trial

Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer

Study acronym: PROSPER
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-09.
Trial Details
NCT Number NCT07531693
Lead Sponsor Institut fuer Frauengesundheit
Collaborators: Lilly Deutschland GmbH Germany, AGO-B Breast Study Group
Conditions HR+/HER2- Early Breast Cancer
Enrollment 200 participants
Start Date 2026-02-19
Primary Completion 2026-09 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-14